Frequency of BCR-ABL gene mutations in Polish patients with chronic myeloid leukemia treated with imatinib: a final report of the MAPTEST study.

@article{Lewandowski2009FrequencyOB,
  title={Frequency of BCR-ABL gene mutations in Polish patients with chronic myeloid leukemia treated with imatinib: a final report of the MAPTEST study.},
  author={Krzysztof Lewandowski and Krzysztof Warzocha and A. Hellmann and Aleksander Bartłomiej Skotnicki and Witold Prejzner and Kajetana Foryciarz and Tomasz Sacha and Michał Gniot and Mirosław Majewski and Iwona Solarska and Grażyna Nowak and Bartosz Wasąg and Mikołaj Kobelski and Cezary Scibiorski and Marek Siemiątkowski and Maria Lewandowska and Mieczysław A. Komarnicki},
  journal={Polskie Archiwum Medycyny Wewnetrznej},
  year={2009},
  volume={119 12},
  pages={789-94}
}
INTRODUCTION The presence of BCR-ABL oncogene mutations in patients with chronic myeloid leukemia (CML) may be responsible for the failure of tyrosine kinase inhibitor treatment. OBJECTIVES The aim of the study was to evaluate the frequency of BCR-ABL gene mutations in patients with CML (the MAPTEST study) treated with imatinib (IM). PATIENTS AND METHODS Direct sequencing analysis of BCR-ABL gene was performed in 92 patients treated with IM for more than 3 months. The mean time of IM… CONTINUE READING